News

Why some people are microdosing popular weight-loss drugs
Some consumers take tiny doses of Ozempic and other GLP-1 drugs or stretch out doses to cut costs and side effects.
Novo slips in obesity-med fight
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
Health on MSN20h
Zepbound or Wegovy? Head-to-Head Trial Says One Is Better for Weight Loss
Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...
Americans scramble as weight-loss drug discounts fall short, copies face crackdown
(Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs ...
Getting medicated has never been easier, and Canberra is worried
Online prescriptions – for everything from weight loss to medicinal cannabis – is now a big business backed by Woolworths and ...
Zacks Investment Research on MSN23h
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This ...